Skip to main content
SpringerLink
Log in

White Adipose Tissue: Beyond Fat Storage

  • Chapter
Obesity

  • 3344 Accesses

Abstract

White adipose tissue is a highly active metabolic and endocrine organ containing adipocytes, connective tissue matrix, nerve tissue, stromovascular and immune cells and secretes many adipokines such as leptin, adiponectin, cytokines, plasminogen activator inhibitor-1, complements components, proteins of the renin-angiotensin system, and resistin, and considered also a major site for metabolism of corticosteroid hormones.

In obesity, increased production of most adipokines having impacts on multiple functions such as appetite and energy balance, insulin sensitivity, angiogenesis, blood pressure, lipid metabolism, all of which are linked with cardiovascular disease. A better understanding of the endocrine function of adipose tissue will likely lead to more rational therapy for these increasingly prevalent disorders. This chapter will provide a brief overview of the metabolic and endocrine functions of adipose tissue.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Giordano A, Smorlesi A, Frontini A, et al. White, brown and pink adipocytes: the extraordinary plasticity of the adipose organ. Eur J Endocrinol. 2014;170:R159–71.

    Article  CAS  PubMed  Google Scholar 

  2. Frontini A, Cinti S. Distribution and development of brown adipocytes in the murine and human adipose organ. Cell Metab. 2010;11:253–6.

    Article  CAS  PubMed  Google Scholar 

  3. Cannon B, Nedergaard J. Brown adipose tissue: function and physiological significance. Physiol Rev. 2004;84:277–359.

    Article  CAS  PubMed  Google Scholar 

  4. Marti A, Berraondo B, Martinez JA. ‘Obese’ protein slims mice. Science. 1995;269:475–6.

    Article  Google Scholar 

  5. Chaldakov GN, Stankulov IS, Hristova M, et al. Adipobiology of disease: adipokines and adipokine-targeted pharmacology. Curr Pharm Des. 2003;9:1023–31.

    Article  CAS  PubMed  Google Scholar 

  6. Ahima RS, Flier JS. Adipose tissue as an endocrine organ. Trends Endocrinol Metab. 2000;11:327–32.

    Article  CAS  PubMed  Google Scholar 

  7. Fruhbeck G, Gomez-Ambrosi J, Muruzabal FJ, et al. The adipocyte: a model for integration of endocrine and metabolic signaling in energy metabolism regulation. Am J Physiol Endocrinol Metab. 2001;280:E827–47.

    CAS  PubMed  Google Scholar 

  8. Ahima RS, Saper CB, Flier JS, et al. Leptin regulation of neuroendocrine systems. Front Neuroendocrinol. 2000;21:263–307.

    Article  CAS  PubMed  Google Scholar 

  9. Ahima RS, Kelly J, Elmquist JK, et al. Distinct physiologic and neuronal responses to decreased leptin and mild hyperleptinemia. Endocrinology. 1999;140:4923–31.

    CAS  PubMed  Google Scholar 

  10. Flier JS. Clinical review 94: what’s in a name? In search of leptin’s physiologic role. J Clin Endocrinol Metabol. 1998;83:1407–13.

    CAS  Google Scholar 

  11. Coleman DL. Effects of parabiosis of obese with diabetes and normal mice. Diabetologia. 1973;9:294–8.

    Article  CAS  PubMed  Google Scholar 

  12. Farooqi IS, Jebb SA, Langmack G, et al. Effects of recombinant leptin therapy in a child with congenital leptin deficiency. N Engl J Med. 1999;341:879–84.

    Article  CAS  PubMed  Google Scholar 

  13. Clement K, Vaisse C, Lahlou N, et al. A mutation in the human leptin receptor gene causes obesity and pituitary dysfunction. Nature. 1998;392:398–401.

    Article  CAS  PubMed  Google Scholar 

  14. Bakker AH, Van Dielen FM, Greve JW, et al. Preadipocyte number in omental and subcutaneous adipose tissue of obese individuals. Obes Res. 2004;12:488–98.

    Article  PubMed  Google Scholar 

  15. Montez JM, Soukas A, Asilmaz E, et al. Acute leptin deficiency, leptin resistance, and the physiologic response to leptin withdrawal. Proc Natl Acad Sci U S A. 2005;102:2537–42.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  16. Wallace AM, McMahon AD, Packard CJ, et al. Plasma leptin and the risk of cardiovascular disease in the West of Scotland Coronary Prevention Study (WOSCOPS). Circulation. 2001;104:3052–6.

    Article  CAS  PubMed  Google Scholar 

  17. Bjorbaek C, Kahn BB. Leptin signaling in the central nervous system and the periphery. Recent Prog Horm Res. 2004;59:305–31.

    Article  CAS  PubMed  Google Scholar 

  18. Flier JS, Harris M, Hollenberg AN. Leptin, nutrition, and the thyroid: the why, the wherefore, and the wiring. J Clin Invest. 2000;105:859–61.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  19. Hileman SM, Pierroz DD, Flier JS. Leptin, nutrition, and reproduction: timing is everything. J Clin Endocrinol Metab. 2000;85:804–7.

    Article  CAS  PubMed  Google Scholar 

  20. Chan JL, Heist K, DePaoli A, et al. The role of falling leptin levels in the neuroendocrine and metabolic adaptation to short term starvation in healthy men. J Clin Invest. 2003;111:1409–21.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  21. Margetic S, Gazzola C, Pegg GG, et al. Leptin: a review of its peripheral actions and interactions. Int J Obes Relat Metab Disord. 2002;26:1407–33.

    Article  CAS  PubMed  Google Scholar 

  22. Lord GM, Matarese G, Howard JK, et al. Leptin modulates the T-cell immune response and reverses starvation-induced immunosuppression. Nature. 1998;394:897–901.

    Article  CAS  PubMed  Google Scholar 

  23. Chandran M, Phillips SA, Ciaraldi T, et al. Adiponectin: more than just another fat cell hormone? Diabetes Care. 2003;26:2442–50.

    Article  CAS  PubMed  Google Scholar 

  24. Fain JN, Madan AK, Hiler ML, et al. Comparison of the release of adipokines by adipose tissue, adipose tissue matrix, and adipocytes from visceral and subcutaneous abdominal adipose tissues of obese humans. Endocrinology. 2004;145:2273–82.

    Article  CAS  PubMed  Google Scholar 

  25. Maeda K, Okubo K, Shimomura I, et al. cDNA cloning and expression of a novel adipose specific collagen-like factor, apM1 (AdiPose Most abundant Gene transcript 1). Biochem Biophys Res Commun. 1996;221:286–9.

    Article  CAS  PubMed  Google Scholar 

  26. Scherer PE, Williams S, Fogliano M, et al. A novel serum protein similar to C1q, produced exclusively in adipocytes. J Biol Chem. 1995;270:26746–9.

    Article  CAS  PubMed  Google Scholar 

  27. Nakano Y, Tobe T, Choi-Miura NH. Isolation and characterization of GBP28, a novel gelatin-binding protein purified from human plasma. J Biochem. 1996;120:803–12.

    Article  CAS  PubMed  Google Scholar 

  28. Hu E, Liang P, Spiegelman BM. AdipoQ is a novel adipose-specific gene dysregulated in obesity. J Biol Chem. 1996;271:10697–703.

    Article  CAS  PubMed  Google Scholar 

  29. Diez JJ, Iglesias P. The role of the novel adipocyte-derived hormone adiponectin in human disease. Eur J Endocrinol. 2003;148:293–300.

    Article  CAS  PubMed  Google Scholar 

  30. Hotta K, Funahashi T, Bodkin NL, et al. Circulating concentrations of the adipocyte protein adiponectin are decreased in parallel with reduced insulin sensitivity during the progression to type 2 diabetes in rhesus monkeys. Diabetes. 2001;50:1126–33.

    Article  CAS  PubMed  Google Scholar 

  31. Kinlaw WB, Marsh B. Adiponectin and HIV-lipodystrophy: taking HAART. Endocrinology. 2004;145:484–6.

    Article  CAS  PubMed  Google Scholar 

  32. Ouchi N, Kihara S, Arita Y, et al. Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin. Circulation. 1999;100:2473–6.

    Article  CAS  PubMed  Google Scholar 

  33. Tan KC, Xu A, Chow WS, et al. Hypoadiponectinemia is associated with impaired endothelium-dependent vasodilation. J Clin Endocrinol Metabol. 2004;89:765–9.

    Article  CAS  Google Scholar 

  34. Yamauchi T, Kamon J, Waki H, et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med. 2001;7:941–6.

    Article  CAS  PubMed  Google Scholar 

  35. Yamauchi T, Kamon J, Waki H, et al. Globular adiponectin protected ob/ob mice from diabetes and ApoE-deficient mice from atherosclerosis. J Biol Chem. 2003;278:2461–8.

    Article  CAS  PubMed  Google Scholar 

  36. Yamauchi T, Kamon J, Minokoshi Y, et al. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med. 2002;8:1288–95.

    Article  CAS  PubMed  Google Scholar 

  37. Bruun JM, Lihn AS, Verdich C, et al. Regulation of adiponectin by adipose tissue-derived cytokines: in vivo and in vitro investigations in humans. Am J Physiol Endocrinol Metab. 2003;285:E527–33.

    Article  CAS  PubMed  Google Scholar 

  38. Pischon T, Girman CJ, Hotamisligil GS, et al. Plasma adiponectin levels and risk of myocardial infarction in men. JAMA. 2004;291:1730–7.

    Article  CAS  PubMed  Google Scholar 

  39. Schulze MB, Shai I, Rimm EB, et al. Adiponectin and future coronary heart disease events among men with type 2 diabetes. Diabetes. 2005;54:534–9.

    Article  CAS  PubMed  Google Scholar 

  40. Lindsay RS, Resnick HE, Zhu J. Adiponectin and coronary heart disease: the Strong Heart Study. Arterioscler Thromb Vasc Biol. 2005;25:15–6.

    Article  CAS  Google Scholar 

  41. Spranger J, Kroke A, Mohlig M, et al. Adiponectin and protection against type 2 diabetes mellitus. Lancet. 2003;361:226–8.

    Article  CAS  PubMed  Google Scholar 

  42. Lindsay RS, Funahashi T, Hanson RL, et al. Adiponectin and development of type 2 diabetes in the Pima Indian population. Lancet. 2002;360:57–8.

    Article  CAS  PubMed  Google Scholar 

  43. Katsuki A, Sumida Y, Murashima S. Serum levels of tumor necrosis factor-alpha are increased in obese patients with noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metabol. 1998;83:859–62.

    CAS  Google Scholar 

  44. Ruan H, Lodish HF. Insulin resistance in adipose tissue: direct and indirect effects of tumor necrosis factor-α. Cytokine Growth Factor Rev. 2003;14:447–55.

    Article  CAS  PubMed  Google Scholar 

  45. Hotamisligil GS. Inflammatory pathways and insulin action. Int J Obes Relat Metab Disord. 2003;27 Suppl 3:S53–5.

    Article  CAS  PubMed  Google Scholar 

  46. Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor- α: direct role in obesity-linked insulin resistance. Science. 1993;259:87–91.

    Article  CAS  PubMed  Google Scholar 

  47. Ruan H, Miles PD, Ladd CM, et al. Profiling gene transcription in vivo reveals adipose tissue as an immediate target of tumor necrosis factor- α: implications for insulin resistance. Diabetes. 2002;51:3176–88.

    Article  CAS  PubMed  Google Scholar 

  48. Yudkin JS, Eringa E, Stehouwer CD. ‘Vasocrine’ signalling from perivascular fat: a mechanism linking insulin resistance to vascular disease. Lancet. 2005;365:1817–20.

    Article  PubMed  Google Scholar 

  49. Boyle PJ. What are the effects of peroxisome proliferator-activated receptor agonists on adiponectin, tumor necrosis factor-alpha, and other cytokines in insulin resistance? Clin Cardiol. 2004;27:1111–6.

    Article  Google Scholar 

  50. Ridker PM, Rifai N, Pfeffer M, et al. Elevation of tumor necrosis factor-alpha and increased risk of recurrent coronary events after myocardial infarction. Circulation. 2000;101:2149–53.

    Article  CAS  PubMed  Google Scholar 

  51. Mohamed-Ali V, Pinkney JK. Adipose tissue as an endocrine and paracrine organ. I J Obes Relat Metab Dis. 1998;22:1145–58.

    Article  CAS  Google Scholar 

  52. Mohamed-Ali V, Goodrick S, Rawesh A, et al. Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-alpha, in vivo. J Clin Endocrinol Metabol. 1997;82:4196–200.

    CAS  Google Scholar 

  53. Fried SK, Bunkin DA, Greenberg AS. Omental and subcutaneous adipose tissues of obese subjects release interleukin-6. Depot difference and regulation by glucocorticoid. J Clin Endocrinol Metabol. 1998;83:847–50.

    CAS  Google Scholar 

  54. Wajchenberg BL. Subcutaneous and visceral adipose tissue: their relation to the metabolic syndrome. Endocr Rev. 2000;21:697–738.

    Article  CAS  PubMed  Google Scholar 

  55. Fernandez-Real JM, Ricart W. Insulin resistance and chronic cardiovascular inflammatory syndrome. Endocr Rev. 2003;24:278–301.

    Article  CAS  PubMed  Google Scholar 

  56. Bastard JP, Jardel C, Bruckert E, et al. Elevated levels of interleukin 6 are reduced in serum and subcutaneous adipose tissue of obese women after weight loss. J Clin Endocrinol Metabol. 2000;85:3338–42.

    CAS  Google Scholar 

  57. Tsigos C, Papanicolaou DA, Kyrou I, et al. Dose-dependent effects of recombinant human interleukin-6 on glucose regulation. J Clin Endocrinol Metabol. 1997;82:4167–70.

    Article  CAS  Google Scholar 

  58. Senn JJ, Klover PJ, Nowak IA, et al. Suppressor of cytokine signaling-3 (SOCS-3), a potential mediator of interleukin-6-dependent insulin resistance in hepatocytes. J Biol Chem. 2003;278:13740–6.

    Article  CAS  PubMed  Google Scholar 

  59. Rotter Sopasakis V, Larsson BM, et al. Short-term infusion of interleukin-6 does not induce insulin resistance in vivo or impair insulin signalling in rats. Diabetologia. 2004;47:1879–87.

    Article  CAS  PubMed  Google Scholar 

  60. De Benedetti F, Alonzi T, Moretta A, et al. Interleukin 6 causes growth impairment in transgenic mice through a decrease in insulin-like growth factor-I. A model for stunted growth in children with chronic inflammation. J Clin Invest. 1997;99:643–50.

    Article  PubMed Central  PubMed  Google Scholar 

  61. Wallenius V, Wallenius K, Ahren B, et al. Interleukin-6-deficient mice develop matureonset obesity. Nat Med. 2002;8:75–9.

    Article  CAS  PubMed  Google Scholar 

  62. Van Harmelen V, Reynisdottir S, Cianflone K, et al. Mechanisms involved in the regulation of free fatty acid release from isolated human fat cells by acylation-stimulating protein and insulin. J Biol Chem. 1999;274:18243–51.

    Article  PubMed  Google Scholar 

  63. Cianflone K, Xia Z, Chen LY. Critical review of acylation-stimulating protein physiology in humans and rodents. Biochim Biophys Acta. 2003;1609:127–43.

    Article  CAS  PubMed  Google Scholar 

  64. Maslowska M, Vu H, Phelis S, et al. Plasma acylation stimulating protein, adipsin and lipids in non-obese and obese populations. Eur J Clin Investig. 1999;29:679–86.

    Article  CAS  Google Scholar 

  65. Holcomb IN, Kabakoff RC, Chan B, et al. FIZZ1, a novel cysteine-rich secreted protein associated with pulmonary inflammation, defines a new gene family. EMBO J. 2000;19:4046–55.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  66. Steppan CM, Bailey ST, Bhat S, et al. The hormone resistin links obesity to diabetes. Nature. 2001;409:307–12.

    Article  CAS  PubMed  Google Scholar 

  67. Banerjee RR, Lazar MA. Resistin: molecular history and prognosis. J Mol Med. 2003;81:218–26.

    CAS  PubMed  Google Scholar 

  68. Steppan CM, Lazar MA. The current biology of resistin. J Int Med. 2004;255:439–47.

    Article  CAS  Google Scholar 

  69. Rajala MW, Obici S, Scherer PE, et al. Adipose-derived resistin and gut-derived resistin-like molecule-beta selectively impair insulin action on glucose production. J Clin Investig. 2003;111:225–30.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  70. Ukkola O. Resistin-a mediator of obesity-associated insulin resistance or an innocent bystander? Eur J Endocrinol. 2002;147:571–4.

    Article  CAS  PubMed  Google Scholar 

  71. Savage DB, Sewter CP, Klenk ES, et al. Resistin/Fizz3 expression in relation to obesity and peroxisome proliferator-activated receptor-action in humans. Diabetes. 2001;50:2199–202.

    Article  CAS  PubMed  Google Scholar 

  72. Reilly MP, Lehrke M, Wolfe ML, et al. Resistin is an inflammatory marker of atherosclerosis in humans. Circulation. 2005;111:932–9.

    Article  CAS  PubMed  Google Scholar 

  73. Ghosh S, Singh AK, Aruna B, et al. The genomic organization of mouse resistin reveals major differences from the human resistin: functional implications. Gene. 2003;305:27–34.

    Article  CAS  PubMed  Google Scholar 

  74. Osawa H, Onuma H, Murakami A, et al. Systematic search for single nucleotide polymorphisms in the resistin gene. The absence of evidence for the association of three identified single nucleotide polymorphisms with Japanese type 2 diabetes. Diabetes. 2002;51:863–6.

    Article  CAS  PubMed  Google Scholar 

  75. Engert JC, Vohl MC, Williams SM, et al. 5′ Flanking variants of resistin are associated with obesity. Diabetes. 2002;51:1629–34.

    Article  CAS  PubMed  Google Scholar 

  76. Wang H, Chu WS, Hemphill C, et al. Human resistin gene: molecular scanning and evaluation of association with insulin sensitivity and type 2 diabetes in Caucasians. J Clin Endocrinol Metabol. 2002;87:2520–4.

    Article  CAS  Google Scholar 

  77. Alessi MC, Peiretti F, Morange P, et al. Production of plasminogen activator inhibitor by human adipose tissue: possible link between visceral fat accumulation and vascular disease. Diabetes. 1997;46:860–7.

    Article  CAS  PubMed  Google Scholar 

  78. Bastelica D, Morange P, Berthet B, et al. Stromal cells are the main plasminogen activator inhibitor-1-producing cells in human fat: evidence of differences between visceral and subcutaneous deposits. Arterioscler Thromb Vasc Biol. 2002;22:173–8.

    Article  CAS  PubMed  Google Scholar 

  79. Mertens I, Van Gaal LF. Obesity, haemostasis and the fibrinolytic system. Obes Rev. 2002;3:85–101.

    Article  CAS  PubMed  Google Scholar 

  80. Juhan-Vague I, Alessi MC, Mavri A, et al. Plasminogen activator inhibitor-1, inflammation, obesity, insulin resistance and vascular risk. J Thromb Haemost. 2003;1:1575–9.

    Article  CAS  PubMed  Google Scholar 

  81. Ailhaud G, Fukamizu A, Massiera F, et al. Angiotensinogen, angiotensin II and adipose tissue development. Int J Obes Relat Metab Dis. 2000;24:S33–5.

    Article  CAS  Google Scholar 

  82. Engeli S, Schling P, Gorzelniak K, et al. The adipose-tissue renin-angiotensin-aldosterone system: role in the metabolic syndrome? Int J Biochem Cell Biol. 2003;35:807–25.

    Article  CAS  PubMed  Google Scholar 

  83. Goossens GH, Blaak EE, van Baak MA. Possible involvement of the adipose tissue renin-angiotensin system in the pathophysiology of obesity and obesity-related disorders. Obes Rev. 2003;4:43–55.

    Article  CAS  PubMed  Google Scholar 

  84. Pollare T, Lithell H, Berne C. A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension. N Engl J Med. 1989;321:868–73.

    Article  CAS  PubMed  Google Scholar 

  85. Rubin GL, Zhao Y, Kalus AM, et al. Peroxisome proliferator receptor gamma ligands inhibit estrogen biosynthesis in human breast adipose tissue: possible implication for breast cancer therapy. Cancer Res. 2000;60:1604–8.

    CAS  PubMed  Google Scholar 

  86. Seckl JR. 11beta-hydroxysteroid dehydrogenases: changing glucocorticoid action. Curr Opin Pharmacol. 2004;4:597–602.

    Article  CAS  PubMed  Google Scholar 

  87. Belanger C, Luu-The V, Dupont P, et al. Adipose tissue intracrinology: potential importance of local androgen/estrogen metabolism in the regulation of adiposity. Horm Metab Res. 2002;34:737–45.

    Article  CAS  PubMed  Google Scholar 

  88. Meseguer A, Puche C, Cabero A. Sex steroid biosynthesis in white adipose tissue. Horm Metab Res. 2002;34:731–6.

    Article  CAS  PubMed  Google Scholar 

  89. Stulnig TM. WaldhauslW 11 β -Hydroxysteroid dehydrogenase type 1 in obesity and type 2 diabetes. Diabetologia. 2004;47:1–11.

    Article  CAS  PubMed  Google Scholar 

  90. Seckl JR, Walker BR. Mini review: 11β-hydroxysteroid dehydrogenase type 1-a tissue-specific amplifier of glucocorticoid action. Endocrinology. 2001;142:1371–6.

    CAS  PubMed  Google Scholar 

  91. Walker BR, Connacher AA, Lindsay RM, et al. Carbenoxolone increases hepatic insulin sensitivity in man: a novel role for 11- oxosteroid reductase in enhancing glucocorticoid receptor activation. J Clin Endocrinol Metab. 1995;80:3155–9.

    CAS  PubMed  Google Scholar 

  92. Xie QW, Kashiwabara Y, Nathan C. Role of transcription factor NF-B/Rel in induction of nitric oxide synthase. J Biol Chem. 1994;269:4705–8.

    CAS  PubMed  Google Scholar 

  93. Goto M, Katayama KI, Shirakawa F, et al. Involvement of NF-B p50/p65 heterodimer in activation of the human prointerleukin-1β gene at two sub regions of the upstream enhancer element. Cytokine. 1999;11:16–28.

    Article  CAS  PubMed  Google Scholar 

  94. O’Rourke L, Gronning LM, Yeaman SJ. Glucose-dependent regulation of cholesterol ester metabolism in macrophages by insulin and leptin. J Biol Chem. 2002;277:42557–62.

    Article  PubMed  CAS  Google Scholar 

  95. Yudkin JS, Kumari M, Humphries SE. Inflammation, obesity, stress and coronary heart disease: is interleukin-6 the link? Atherosclerosis. 2000;148:209–14.

    Article  CAS  PubMed  Google Scholar 

  96. Ridker PM, Rifai N, Rose L, et al. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med. 2002;347:1557–65.

    Article  CAS  PubMed  Google Scholar 

  97. Fukuhara A, Matsuda M, Nishizawa M. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science. 2005;307:426–30.

    Article  CAS  PubMed  Google Scholar 

  98. Stentz FB, Umpierrez GE, Cuervo R. Proinflammatory cytokines, markers of cardiovascular risks, oxidative stress, and lipid peroxidation in patients with hyperglycemic crises. Diabetes. 2004;53:2079–86.

    Article  CAS  PubMed  Google Scholar 

  99. Cai H, Li Z, Dikalov S, et al. NAD (P) H oxidase-derived hydrogen peroxide mediates endothelial nitric oxide production in response to angiotensin II. J Biol Chem. 2002;277:48311–7.

    Article  CAS  PubMed  Google Scholar 

  100. Widlansky ME, Gokce N, Keaney JF, et al. The clinical implications of endothelial dysfunction. J Am Coll Cardiol. 2003;42:1149–60.

    Article  CAS  PubMed  Google Scholar 

  101. Kawanami D, Maemura K, Takeda N, et al. Direct reciprocal effects of resistin and adiponectin on vascular endothelial cells: a new insight into adipocytokine–endothelial cell interactions. Biochem Biophys Res Commun. 2004;314:415–9.

    Article  CAS  PubMed  Google Scholar 

  102. Verma S, Li SH, Wang CH. Resistin promotes endothelial cell activation: further evidence of adipokine–endothelial interaction. Circulation. 2003;108:736–40.

    Article  CAS  PubMed  Google Scholar 

  103. Jambrik Z, Venneri L, Varga A, et al. Peripheral vascular endothelial function testing for the diagnosis of coronary artery disease. Am Heart J. 2004;148:684–9.

    Article  PubMed  Google Scholar 

  104. Calabro P, Samudio I, Willerson JT, et al. Resistin promotes smooth muscle cell proliferation through activation of extracellular signal-regulated kinase 1/2 and phosphatidylinositol 3-kinase pathways. Circulation. 2004;110:3335–40.

    Article  CAS  PubMed  Google Scholar 

  105. Pinkney JH, Stehouwer CD, Coppack SW, et al. Endothelial dysfunction: cause of the insulin resistance syndrome. Diabetes. 1997;46:S9–13.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Internal Medicine, Al Mouwasat Hospital, Jubail, Kingdom of Saudi Arabia

    Syed Khalid Imam

Authors
  1. Syed Khalid Imam
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Syed Khalid Imam .

Editor information

Editors and Affiliations

  1. School of Science and Technology, Nottingham Trent University, Nottingham, United Kingdom

    Shamim I. Ahmad

  2. Al Mouwasat Hospital, Jubail, Saudi Arabia

    Syed Khalid Imam

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Imam, S.K. (2016). White Adipose Tissue: Beyond Fat Storage. In: Ahmad, S., Imam, S. (eds) Obesity. Springer, Cham. https://doi.org/10.1007/978-3-319-19821-7_1

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-19821-7_1

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-19820-0

  • Online ISBN: 978-3-319-19821-7

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation